Estland - estisk - Ravimiamet

ranbaxy uk ltd. - memantiin - õhukese polümeerikattega tablett - 10mg 98tk; 10mg 112tk; 10mg 28tk; 10mg 100tk; 10mg 56tk; 10mg 30tk; 10mg 60tk; 10mg 42tk

Estland - estisk - Ravimiamet

ranbaxy (u.k.) limited - pantoprasool - gastroresistentne tablett - 20mg 28tk; 20mg 7tk

Den europeiske union - estisk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - estisk - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapiin-naatrium - bakteriaalsed infektsioonid - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 ja 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Den europeiske union - estisk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Den europeiske union - estisk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Estland - estisk - Ravimiamet

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 22,7mg 1ml 2.5l 5tk; 22,7mg 1ml 1.5l 6tk; 22,7mg 1ml 2.5l 4tk; 22,7mg 1ml 2l 5tk

Estland - estisk - Ravimiamet

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 38,6mg 1ml 2.5l 5tk; 38,6mg 1ml 2.5l 4tk; 38,6mg 1ml 2l 4tk; 38,6mg 1ml 2l 5tk

Estland - estisk - Ravimiamet

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 13,6mg 1ml 2l 5tk; 13,6mg 1ml 2.5l 5tk; 13,6mg 1ml 1.5l 5tk; 13,6mg 1ml 1.5l 6tk

Estland - estisk - Ravimiamet

oÜ baxter estonia - hüpertoonilised lahused - peritoneaaldialüüsilahus - 2,27% 1500ml 5tk; 2,27% 3000ml 3tk; 2,27% 1500ml 6tk; 2,27% 2000ml 5tk; 2,27% 2500ml 3tk; 2,27% 2500ml 4tk